KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Receivables - Other: 2009-2024

Historic Receivables - Other for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $92.2 million.

  • Ionis Pharmaceuticals' Receivables - Other rose 37.26% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 37.26%. This contributed to the annual value of $92.2 million for FY2024, which is 5.72% down from last year.
  • According to the latest figures from FY2024, Ionis Pharmaceuticals' Receivables - Other is $92.2 million, which was down 5.72% from $97.8 million recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Receivables - Other peaked at $97.8 million during FY2023, and registered a low of $25.5 million during FY2022.
  • Its 3-year average for Receivables - Other is $71.8 million, with a median of $92.2 million in 2024.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Receivables - Other slumped by 58.74% in 2022 and then soared by 282.87% in 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Receivables - Other (Yearly) stood at $76.2 million in 2020, then decreased by 18.78% to $61.9 million in 2021, then tumbled by 58.74% to $25.5 million in 2022, then spiked by 282.87% to $97.8 million in 2023, then declined by 5.72% to $92.2 million in 2024.